


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-16 (cancelled)

Claim 17 (currently amended): A separation matrix for affinity chromatography, comprising ligands coupled to a support, wherein the majority of the ligands are the compounds of formula (I)



(I)

wherein

R<sub>1</sub> is CH<sub>3</sub> or CH<sub>2</sub>CH<sub>3</sub>;

R<sub>2</sub> is a ~~*para* and/or *meta*~~ substituted-phenyl group that has been substituted with Cl in *meta* and *para* position having substituents selected from the group consisting of F, Cl, Br, I, OH and a group —O—R<sub>5</sub>, wherein R<sub>5</sub> is either CH<sub>2</sub> or CH<sub>2</sub>CH<sub>3</sub>;

R<sub>3</sub> is H, CH<sub>3</sub> or CH<sub>2</sub>CH<sub>3</sub>; and

R<sub>4</sub> is a linear or cyclic aliphatic group,

or, wherein

R<sub>1</sub> and R<sub>2</sub> are as stated above while R<sub>3</sub> and R<sub>4</sub> are parts of a 4- to 6-membered cyclic entity,

and which compound has affinity for human IgG of  $\kappa$ -type;

further wherein said ligands are coupled to said support through the group R<sub>4</sub>.

Claim 18 (previously presented): The separation matrix of claim 17, wherein the ligands have been coupled to the support via linkers.

Claim 19 (previously presented): The separation matrix of claim 17, wherein the support is a porous polymeric particle.

Claim 20 (cancelled)

Claim 21 (withdrawn): A system suitable for affinity chromatography, comprising the separation matrix of claim 17 packed in a column.

Claim 22 (previously presented): The separation matrix of claim 17, wherein the compounds of formula (I) is an affinity ligand with affinity for the constant region of a Fab fragment of human IgG of  $\kappa$ -type.

Claim 23 (previously presented): The separation matrix of claim 17, wherein R<sub>1</sub> is CH<sub>3</sub>.

Claims 24-27 (cancelled)

Claim 28 (previously presented): The separation matrix of claim 17, wherein R<sub>4</sub> is an aliphatic group, which includes oxygen atoms in one or more positions.

Claim 29 (previously presented): The separation matrix of claim 17, wherein R<sub>4</sub> is an aliphatic group, which contains one or more carbonyl groups.

Claim 30 (cancelled)

Claim 31 (currently amended): The separation matrix of claim 17, wherein R<sub>1</sub> is CH<sub>3</sub>; ~~R<sub>2</sub> is a phenyl group that has been substituted with Cl in *meta* and *para* position;~~ and R<sub>3</sub> and R<sub>4</sub> are parts of a cyclic 5-membered group.

Claim 32 (previously presented): The separation matrix of claim 31, wherein the cyclic 5-membered entity is substituted in a position directly adjacent to N with a C(O)-O-CH<sub>3</sub> group.

Claim 33 (previously presented): The separation matrix of claim 17, wherein said compounds of formula (I) are capable of binding to the constant region of a human

IgG of  $\kappa$ -type, or a functional derivative thereof, with a binding constant of at least  $10^{-3}$  M.

Claim 34 (previously presented): The separation matrix of claim 17, wherein said compounds of formula (I) are capable of binding to the constant region of a human IgG of  $\kappa$ -type, or a functional derivative thereof, via a binding pocket-defined by the structure coordinates of the amino acids as shown in Fig 6.